Sustainability at Biocon

Biosimilar strategy resulted in several 'firsts' Biocon 1 Achieved many firsts in the space despite the nascent biosimilars regulatory pathway, setting new benchmarks for the industry 2004 2017 2018 - ..2021 1st company to commercialize human insulin using proprietary P. pastoris platform 1st company to receive approval for bTrastuzumab in the US 1st company to receive approval for bPegfilgrastim in the US 1st company to receive interchangeability for a biosimilar (glargine) in the US 14

View entire presentation